Monthly Archives: October 2022

Husband and Wife Team Bring Regenerative Medicine Clinic to Jackson – Franchising.com

Posted: October 13, 2022 at 2:31 am

By: QC Kinetix | 0Shares 159Reads

October 10, 2022 // Franchising.com // JACKSON, Tenn. - QC Kinetix recently opened in Jackson and offers one of the most advanced regenerative medicine protocols in Western Tennessee.

Brian and Andrea Weed are the husband-and-wife business team bringing regenerative medicine to Jackson with their new clinic. The couple used to work in healthcare on the non-clinical side of the industry - Brian as the CEO and Andrea in sales. Now the two are looking to help improve lives through regenerative medicine. They have three sons: one having been in combat in the Afghanistan war and two who played college sports. All have sustained an injury or two.

We have seen our fair share of sports injuries and we know the toll physically and emotionally it takes on when they are forced to take time off, says Andrea. With regenerative medicine treatments, they can bounce back quicker.

The Weeds set up an exceptional team to treat the community, that includes their clinic manager Danielle Moore. Her background is in kinesiology, where she worked in physical therapy for several years and then in personal training before finding regenerative medicine.

I am always looking for ways to naturally treat ailments. When I found we can use our own body to repair itself through regenerative medicine I knew I needed to bring awareness to it, says Moore. We are already having patients who say they are feeling better compared to the first day they walked through our clinics doors.

QC Kinetix uses all-natural biologic protocols to stimulate the body to repair or heal its own damaged tissues and joints. Its an alternative to surgery, NSAIDs, and pain pills that mask the pain but dont repair the problem. For patients seeking relief from pain due to musculoskeletal injury, chronic joint pain, or hip, knee, back, or shoulder pain, regenerative procedures are the next frontier for treatment.

Former Dallas Cowboys great and NFL MVP Emmitt Smith is the official spokesperson for QC Kinetix. He knows firsthand the need for innovative chronic pain treatments that help people get back to their active lifestyles. It used to be only elite athletes like Smith had access to regenerative medicine treatments, but rapid growth and innovation in the field have made the treatments accessible to everyone.

So many Jackson residents will benefit from these treatments, from those who have retired to anyone enjoying an active lifestyle, as well as athletes and industry workers who cant afford a long surgery recovery, says Weed.

Regenerative medicine can be used to address a wide variety of health conditions. The Weeds and their team are excited to begin providing hair restoration treatment options for men and women in the near future.

Scott Hoots, CEO of Charlotte-based QC Kinetix, is confident that the Weeds and their team will be a tremendous asset to the QC Kinetix franchise.

Brian and Andrea are ideal QC Kinetix franchisees, says Hoots. Their background in business and sports combined with their love of regenerative medicine makes the Weeds a perfect candidate for us. We cant wait to see their business grow, and more Western Tennessee residents see the benefits of these treatments firsthand.

QC Kinetix is a type of concierge medicine, which continues to grow in popularity. There are none of the difficulties of dealing with insurance companies. Patients pay cash and get a very high level of care and service with state-of-the-art treatments. Every patient receives quality time with their medical provider and a customized plan of treatment based on their individual diagnosis and condition.

QC Kinetix Jackson operates at 3014 Greystone Square, Jackson, TN 38305.

SOURCE QC Kinetix

###

The rest is here:
Husband and Wife Team Bring Regenerative Medicine Clinic to Jackson - Franchising.com

Posted in Regenerative Medicine | Comments Off

Hundreds run for regenerative medicine research at the 2022 TCS London Marathon – British Heart Foundation

Posted: October 13, 2022 at 2:31 am

Around 800 BHF runners took to the streets of the British capitalfor the iconic 2022 TCS London Marathon on Sunday 2nd October.

As the 2022 Charity of the Year, our runners have raised nearly 2 million so far, with further donations expected. This will help fund lifesaving science into regenerative medicine, a cutting-edge field of research that has the power to unlock a cure for heart failure.

Among ourmarathon runners was Professor Sanjay Sinha from the University of Cambridge, who completed the event in around four hours fifty minutes.

Professor Sanjay is leading ground-breaking research behind the Heart Healing Patch. Made of stem cells, the patch could be applied to the heart to help repair damage caused by a heart attack and could help save and improve the lives of millions worldwide affected by heart failure.

Nearly a million people in the UK are currently living with heart failure. Poignantly, Sanjays running number for the marathon was 17,000 which is how many people are diagnosed with heart failure in the UK each month.

After crossing the finish line Professor Sanjay Sinha, our Senior Clinical Research Fellow at the University of Cambridge, said: Taking part in the 2022 TCS London Marathon for the British Heart Foundation (BHF), was such a huge challenge. It was my first marathon and an absolutely incredible experience. The atmosphere on the day was electric and I wouldnt have made it round the last few miles without the support from the crowds, who were amazing.

"I am proud to know that by doing this, together with over 800 other BHF runners, weve helped the BHF to continue to fund pioneering research into regenerative medicine including the development of our Heart Healing Patch, which could save and improve the lives of millions of people worldwide affected by heart failure.

The money raised by the BHFs runners and supporters at this years event could be truly transformative and help us carry out the first clinical trials of the patch in patients. I want to thank every single person who has already donated.

Our Chief Executive Dr Charmaine Griffiths said: It was a truly heart-warming and inspirational day cheering on all our Team BHF runners, made even more special with the BHF being the 2022 TCS London Marathons charity of the year.

The hundreds of runners who took part in the iconic TCS London Marathon 2022 have helped us to turbo charge our pioneering research into regenerative medicine, which includes the development of a Heart Healing Patch, which could save and improve the lives of millions of people worldwide affected by heart failure.

From all those who fundraised, donated, volunteered and supported Team BHF on the day, you have played your part in helping to get our ground-breaking research over the finish line even faster and we cannot thank you enough.

Applications for the 2023TCS London Marathon are now open.

Help to make the Heart Healing Patch a reality

See the original post:
Hundreds run for regenerative medicine research at the 2022 TCS London Marathon - British Heart Foundation

Posted in Regenerative Medicine | Comments Off

Frequency Therapeutics Completes Enrollment of Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss – Yahoo Finance

Posted: October 13, 2022 at 2:31 am

Study of Therapeutic to Restore Hearing Aims to Show Speech Perception Improvements in Individuals with Noise-Induced or Permanent Sudden Sensorineural Hearing Loss

Company Aligned with FDA on Speech Perception Primary Endpoint

Readout Expected in Q1 2023

LEXINGTON, Mass., October 12, 2022--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a persons innate potential to restore function, today announced that it has completed enrollment of its placebo-controlled Phase 2b study of FX-322 in adults with acquired sensorineural hearing loss (SNHL). The FX-322-208 study, which enrolled 142 individuals, is designed to show improvement in a pre-specified measure of speech perception. The Company plans to release study data in the first quarter of 2023.

"I am very pleased with our teams execution of this study for the first potential treatment to restore hearing for those with SNHL. The 208 study was rigorously designed to ensure the stability of an individuals hearing prior to entering the trial and to exclusively enroll those with the types hearing loss where we observed the strongest hearing improvement in prior FX-322 studies. FX-322 continues to have a favorable safety profile and we are aligned with FDA on the primary speech perception endpoint. With a successful outcome of this single-dose study, our intent is to advance the program into Phase 3 trials," said David L. Lucchino, Frequencys chief executive officer.

Mr. Lucchino continued: "We are grateful to all the study volunteers, clinicians and site staff for their time and commitment to this trial. We believe the high level of interest from patients and healthcare providers in this study further demonstrates the need for a novel, disease modifying hearing loss treatment to expand the standard of care for the millions of individuals with sensorineural hearing loss."

Story continues

FX-322-208 Study Design

FX-322-208 is a prospective, randomized, double-blinded, placebo-controlled, multi-center Phase 2b study designed to evaluate the efficacy of a single administration of FX-322 on speech perception in subjects aged 18-65 with hearing loss associated with either noise-induced or permanent idiopathic sudden SNHL. The study enrolled 142 participants, exceeding the original enrollment target of approximately 124, and is being conducted at 28 clinical sites across the US.

The Company previously aligned with the US Food and Drug Administration (FDA) on the use of the specific speech perception primary endpoint. With improved speech perception, individuals may hear words more clearly, a critical unmet need for individuals with hearing loss. The FX-322-208 study is powered at 80% (significance level of 0.05) to observe a statistically significant and clinically meaningful improvement in speech perception at day 90 following dosing, with study responders defined as individuals exceeding the upper 95% confidence interval in the speech perception test. The Company has not publicly disclosed the specific test used for the primary endpoint to maximize the rigor of the study and mitigate potential bias.

During the study, subjects participate in a range of audiologic exams, including pure-tone audiometry, word recognition in quiet, word recognition in noise, the Tinnitus Functional Index (TFI), as well as multiple patient-reported outcome measures including Frequencys proprietary patient reported outcome instrument (RADIAL) in acquired SNHL. All subjects are required to have a documented audiogram from at least six months prior to screening and most patients are evaluated over a 270-day period following dosing. The studys rigorous design includes a lead-in phase with multiple baseline measures. Subjects with instability of baseline tests are disqualified from participation in the study. Study audiometry testing sessions are recorded and monitored by third party audiologists to ensure consistency and identify any anomalies related to how tests were conducted.

In prior studies, the Company observed the greatest concentration of speech perception improvements in individuals with permanent sudden or noise-induced sensorineural hearing loss in the moderate to lower severe hearing loss range. These learnings informed the design and inclusion criteria for the FX-322-208 study. More than 200 individuals have been dosed with a single injection of FX-322 in prior or ongoing studies, and the drug candidate has continued to exhibit a favorable safety profile with no drug-related serious adverse events.

About Sensorineural Hearing Loss

Sensorineural hearing loss is the most common form of hearing loss, typically resulting from damage to sensory hair cells in the cochlea. These cells convert sound waves to signals sent to the brain which are interpreted as speech and sound. Sensory hair cells are lost due to chronic noise exposure, aging, certain viral infections or exposure to drugs that are toxic to the ear. This type of hearing loss impacts around 40 million individuals in the U.S. alone.

About Frequency Therapeutics

Frequency Therapeutics is leading a new category in regenerative medicine that aims to restore human function first in hearing loss and then in multiple sclerosis by developing therapeutics that activate a persons innate regenerative potential within the body through the activation of progenitor cells. Frequencys hearing research focuses on cochlear restoration and auditory repair, and its lead asset, FX-322, is a small-molecule combination product candidate that is the first to show statistically significant and clinically meaningful hearing improvements in clinical trials for sensorineural hearing loss. Frequency is also following early restorative signals in MS to develop medicines with the same underlying regenerative science being brought to hearing loss.

Headquartered in Lexington, Mass., Frequency has an ex-U.S. license and collaboration agreement with Astellas Pharma Inc. for FX-322, as well as additional collaboration and licensing agreements with academic and nonprofit research organizations including Massachusetts Eye and Ear, Mass General Brigham, the Massachusetts Institute of Technology, and the Scripps Research Institute.

For more information, visit http://www.frequencytx.com and follow Frequency on Twitter @Frequencytx.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the timing and design of the Phase 2b study (FX-322-208), including the timing of results and the ability of design features to reduce bias, the commencement of any future FX-322 trials, the interpretation and implications of the results and learnings of other FX-322 clinical studies, the treatment potential of FX-322, estimates of the size of the hearing loss population, the acceptance by the FDA of particular endpoints in the Companys trials, and the potential application of the progenitor cell activation (PCA) platform to other diseases.

These forward-looking statements are based on managements current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the impact of COVID-19 on the Companys ongoing and planned clinical trials, research and development and manufacturing activities, the Companys business and financial markets; the Company has incurred and will continue to incur significant losses and is not and may never be profitable; the Companys need for additional funding to complete development and commercialization of any product candidate; the Companys dependence on the development of FX-322; the unproven approach of the PCA platform and the inability to identify additional potential product candidates; the lengthy, expensive and uncertain process of clinical drug development and regulatory approval; the Companys limited experience successfully obtaining marketing approval for and commercializing product candidates; the results of earlier clinical trials not being indicative of the results from later clinical trials; differences between preliminary or interim data and final data; adverse events or undesirable side effects; disruptions at the FDA and other regulatory agencies; failure to identify additional product candidates; new or changed legislation; failure to maintain Fast Track designation for FX-322 and such designation failing to result in faster development or regulatory review or approval; ability to seek and receive Breakthrough Therapy designation for FX-322; the Companys ability to enroll and retain patients in clinical trials; costly and damaging litigation, including related to product liability or intellectual property or brought by stockholders; dependence on Astellas Pharma Inc. for the development and commercialization of FX-322 outside of the United States; misconduct by employees or independent contractors; reliance on third parties, including to conduct clinical trials and manufacture product candidates; compliance with changing laws and regulations, including healthcare and environmental, health, data privacy and safety laws and regulations; failure to obtain, maintain and enforce protection of patents and other intellectual property rights covering product candidates; security breaches or failure to protect private personal information; attracting and retaining key personnel; and the Companys ability to manage growth.

These and other important factors discussed under the caption "Risk factors" in the Companys Form 10-Q filed with the Securities and Exchange Commission (SEC) on August 9, 2022 and its other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent managements estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing the Companys views as of any date subsequent to the date of this press release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221012005144/en/

Contacts

Investor:Carlo Tanzi, Ph.D.Kendall Investor Relationsctanzi@kendallir.com 617-914-0008

Media:Frequency TherapeuticsEmail: media@frequencytx.com

See original here:
Frequency Therapeutics Completes Enrollment of Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss - Yahoo Finance

Posted in Regenerative Medicine | Comments Off

3D Bioprinting Market Size to Touch Valuation of $1.5 Billion by 2028 | Inkjet Technology Generates More than 38% Revenue of Bioprinting Market -…

Posted: October 13, 2022 at 2:31 am

WASHINGTON, Oct. 09, 2022 (GLOBE NEWSWIRE) -- Global 3D bioprinting market was valued at USD 1.5 Billion in 2021 and is projected to attain a value of USD 3.7 Billion by 2028 during the forecast period, 20222028.

Get Sample Copy of This Report: https://www.vantagemarketresearch.com/3d-bioprinting-market-1235/request-sample

As the demand for bioprinting continues to increase, so too does the need for 3D bioprinting. 3D bioprinting market uses small droplets of cell-containing material to create 3D objects in vitro It is useful for creating organs, tissues, and other structures from stem cells or other cells. It is also useful for creating customized implants and drugs.

The growing demand for 3D bioprinting has led to the development of new technologies and processes that make it easier and faster to create 3D objects. As the technology opens up new opportunities for the development of novel medical treatments, 3D bioprinting market growth is being driven by the increasing demand for personalized medicine, as well as the increasing need for customized structures and therapies. With each passing year, the technology is also becoming more affordable and accessible, making it an attractive option for clinical applications. This growth in demand will likely continue to accelerate in the future, as further advances in technology are made.

Top Players in Global 3D Bioprinting Market

Bioprinting is booming as a technology for creating tissue and organ replacement parts. The following are three factors driving demand for this innovative technology:

1. Growing aging population: The worlds population is growing older, which means there will be an increasing need for tissue and organ replacements. Bioprinting can help to fill this need by creating replacement tissues and organs from patient-specific cells. Over 1 billion people are above 60 years old and the number is projected to expand to 1.4 billion by 2050.

2. Declining supplies of natural organs and tissues: The availability of natural organs and tissues for transplantation is dwindling in worldwide 3D bioprinting market due to the increasing incidence of diseases such as Alzheimers, heart failure, and cancer. By using bioprinting, hospitals can create replacement tissues or organs specifically tailored to the needs of individual patients.

3. Progress in regenerative medicine: Regenerative medicine utilizes techniques such as cell therapy and 3D printing to restore function to damaged or diseased tissue. By printing tissue components in a controlled environment, regenerative medicine providers are able to engineers complex tissue constructs that would otherwise be extremely difficult or impossible to achieve.

Immediate Delivery Available | Buy this Premium Research Report@ https://www.vantagemarketresearch.com/buy-now/3d-bioprinting-market-1235/0

Key Findings:

Scope of the Report:

Increasing Adoption of 3D Bioprinting for Engineering Organs

3D bioprinting market is becoming an increasingly important as it enables the rapid, low-cost fabrication of complex components and structures from a variety of biocompatible materials. Vantage Market Research estimates that global spending on 3D printing services will top $2.3 billion by 2025, with growth rates well above the average for all software categories over the same period.

3D bioprinting market currently has niche applications in large-scale industrial production, but its potential to create low-cost human tissues and organs has drawn considerable interest. This is due in part to the high degree of customization that is possible with 3D bioprinting, which can enable precise control over tissue properties, including shape, size, and composition.

Every year, more than 10,000 Americans are put on waiting list for organ transplantation and over 6,000 of them die due to shortage or inability to get the suitable donor. This represents a huge opportunity for the players active in the global 3D bioprinting market to incentivize this revenue opportunity by engineering organ at scale to meet the demand and supply gap.

In fact, bioprinting is an emerging technology that enables the printing of nearly any type of biological tissue and organ. This technology has already been used to create structures such as heart valves, skin patches, and bone implants. However, there are still many applications for bioprinting that have yet to be explored.

3D printing is revolutionizing the way products are designed, and it is now being used to create organs at scale. By printing organs in a customized manner, we can improve the accuracy, predictability, and efficiency of organ printing.

There are many different types of organs that could benefit from bioprinting. Examples of organs that could be printed using this technology include lungs, liver, kidneys, and hearts. With bioprinting, surgeons could potentially print new organs onsite if they become damaged or diseased.

The applications for 3D bioprinting market are endless, and we are just starting to scratch the surface of what this technology can do. We believe that bioprinting will play a major role in engineering organ at scale in the future.

Download Full Report (176 Pages PDF with Insights, Charts, Tables, Figures) at@ https://www.vantagemarketresearch.com/industry-report/3d-bioprinting-market-1235

As per Vantage Market Research, end-users and scientist have started paying attention to making use of 3D bioprinting on large scale thanks to numerous benefits of using 3D bioprinting for organ engineering. Some of the most important benefits include:

Browse market data Tables and Figures spread through 176 Pages and in-depth TOC on "3d Bioprinting Market by Technology (Inkjet-based, Magnetic Levitation, Syringe-based, Laser-based), by Application (Medical, Dental, Biosensors, Consumer/Personal Product Testing), by Region (North America, Latin America, Europe, Asia Pacific) - Global Industry Assessment (2016 - 2021) & Forecast (2022 - 2028)".

Inkjet Technology Generates More than 38% Revenue of Bioprinting Market

3D bioprinting market is becoming popular due to its versatility and ability to create complex tissue structures. However, one disadvantage of 3D bioprinting is the need for magnetic levitation technology in order to print large objects. Inkjet technology is becoming more popular for 3D bioprinting due to its lower printing costs and the ability to print larger objects. Inject technology uses a syringe filled with liquid bioprinters to create realistic tissue constructs.

Some of the biggest advantages of inkjet technology in the global 3D bioprinting market include its low cost and the ability to print complex tissue constructs. Inkjet printers can also produce large quantities of tissue at once, which makes them ideal for medical applications. Deploying inject printers in hospitals could improve the quality of patient care by allowing for faster production of customized tissue constructs. In addition, inject printers could help to reduce the cost of healthcare by reducing the need for magnetic levitation technology.

As per Vantage Market Research, most of the users in the global 3D bioprinting market prefer inkjet bioprinting technology because the printing can be faster and more accurate than magnetic levitation printing. Second, inkjet printing does not require the use of a cold bed or vacuum chamber both of which can be time-consuming and expensive to set up. Third, inkjet printing is less likely to produce errors due to materials incompatibility than magnetic levitation printing. Inkjet printing is also better at reproducing delicate features and patterns than magnetic levitation printing.

Overall, inkjet technology is becoming more popular for 3D bioprinting due to its speed, accuracy, and versatility.

Key Questions Answered in The Report:

Customization of the Report:

The report can be customized as per client needs or requirements. For any queries, you can contact us on sales@vantagemarketresearch.com or +1 (202) 380-9727. Our sales executives will be happy to understand your needs and provide you with the most suitable reports.

Browse More Related Report:

About Vantage Market Research:

We, at Vantage Market Research, provide quantified B2B high quality research on more than 20,000 emerging markets, in turn, helping our clients map out constellation of opportunities for their businesses. We, as a competitive intelligence market research and consulting firm provide end to end solutions to our client enterprises to meet their crucial business objectives. Our clientele base spans across 70% of Global Fortune 500 companies. The company provides high quality data and market research reports. The company serves various enterprises and clients in a wide variety of industries. The company offers detailed reports on multiple industries including Chemical Materials and Energy, Food and Beverages, Healthcare Technology, etc. The companys experienced team of Analysts, Researchers, and Consultants use proprietary data sources and numerous statistical tools and techniques to gather and analyse information.

Eric Kunz

6218 Georgia Avenue NW Ste 1 - 564

Washington DC 20011-5125

United States Tel: +1 202 380 9727

Email: sales@vantagemarketresearch.com

Website: https://www.vantagemarketresearch.com/

Latest Vantage Market Research Press Releases @https://www.vantagemarketresearch.com/insight/press-releases

Latest Vantage Market Research Blog @ https://www.vantagemarketresearch.com/insight/blogs

Blog:

See more here:
3D Bioprinting Market Size to Touch Valuation of $1.5 Billion by 2028 | Inkjet Technology Generates More than 38% Revenue of Bioprinting Market -...

Posted in Regenerative Medicine | Comments Off

SANUWAVE’s Energy First Technology to be Featured in 3 Clinical Posters at Upcoming 2022 Fall Symposium on Advanced Wound Care (SAWC) -…

Posted: October 13, 2022 at 2:31 am

EDEN PRAIRIE, MN, Oct. 12, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire SANUWAVE Health, Inc. (OTCPK: SNWV), a leading provider of next-generation wound care products, is excited to announce that three abstracts highlighting the role of the companys dermaPACE system in clinical cases were accepted to the Poster Presentation Hall at the upcoming 2022 Fall Symposium on Advanced Wound Care (SAWC) hosted by HMP Global. The conference is one of wound cares most esteemed events and will take place at Caesars Palace, Las Vegas, Nevada from October 13-16, 2022.

The following clinical cases, which examine the use of dermaPACE in patients with chronic, complex, and challenging wounds, will be presented.

1.) The Use of Non-Invasive Extracorporeal Shockwave Therapy (ESWT) Pulsed Acoustic Cellular Expression (PACE) System In Complex Wounds Related To Erythromelalgia, A Rare Skin Condition.

Dr. Marcelo de Oliveira e Silva, HOSPITAL CAXIAS DOR RIO DE JANEIRO general and plastic surgeon, UNIFESP Medical School Professor, Pontifical Catholic University (PUC) Carlos Chagas Medical Graduate Institute, coordinator, Quinta D'Or Hospital, specialist, evaluator, Brazilian Society of Plastic Surgery (SBCP), preceptor, Ivo Pitanguy Institute.

Dr. Paulo Roberto Castelleti Liborio Da Costa Brazilian Society of Plastic Surgery and Ivo Pitanguy Institute. Practices at Salgado Filho Municipal Hospital (Trauma Surgery,General Surgery) and Duque de Caxias DOr Hospital as Plastic Surgeon

2.) Extracorporeal Shockwave Therapy (ESWT) PACE-Technology: Pilot Trial to Treat Mixed Etiologies Lower Leg Ulcer in a Mobile Setting; When All Else Failed

John David Thomas, MD, FAPWCA Medical Director Solutions Medical Group, PLLC, Houston, TX. DIRECTOR OF WOUND CARE: Signature Home Health Baytown, TX; The Heights of North Houston Spring, TX; Park Manor, The Woodlands The Woodlands, TX; IPR Healthcare Systems Houston, TX; Crimson Heights Humble, TX. SPEAKER: Kerecis Omega3 Fish Skin technology. FORMER-SPEAKER: Acelity / KCI San Antonio, TX; Tissue Regenix Woundcare Inc. San Antonio, TX

3.) Extracorporeal Shockwave Therapy (ESWT) Pace-Technology: A New Approach to an Old Nemesis-Pyoderma Gangrenosum

Dr Perry Mayer; Medical Director of The Mayer Institute (TMI), Center of Excellence Hamilton Ontario Canada

Representatives from SANUWAVE will be available at SAWC booth #619 in the exhibit hall for inquiries on their ENERGY FIRST product portfolio which includes both dermaPACE and UltraMIST. The companys CEO, Kevin Richardson, and CRO, Jack Schlechtweg, will also be in attendance.

If you are attending the event and would like to schedule some time to meet with a team member, please email the companys Marketing contact Sabrina Ruelle at Sabrina.Ruelle@Sanuwave.com so she can help facilitate a meet time.

Additional information regarding SANWUAVEs product portfolio is available through their website at https://sanuwave.com/

About SANUWAVE

SANUWAVE Health is focused on the research, development, and commercialization of its patented, non-invasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures.

SANUWAVEs end-to-end wound care portfolio of regenerative medicine products and product candidates help restore the bodys normal healing processes. SANUWAVE applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions.

Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Companys ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the regulatory approval and marketing of the Companys product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Companys ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Companys periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.

INVESTOR RELATIONS CONTACT:Investorrelations@Sanuwave.com

2022 GlobeNewswire, Inc., source Press Releases

See original here:
SANUWAVE's Energy First Technology to be Featured in 3 Clinical Posters at Upcoming 2022 Fall Symposium on Advanced Wound Care (SAWC) -...

Posted in Regenerative Medicine | Comments Off

Stem Cell Therapy for Knees – thriveMD Denver & Vail, CO

Posted: October 13, 2022 at 2:30 am

Articular cartilage damage, especially when it affects the knee joint, remains a major clinical problem due to the poor intrinsic ability for this tissue to repair itself. The major function of joint cartilage is to allow for smooth gliding of joint surfaces and to protect the surrounding bone from stress. This sort of movement is key for individuals who participate in sports such as skiing. In a wider context, though, knee cartilage damage can prevent people from running, exercising, or just moving as freely as theyd like. Articular cartilage allows the knee to absorb shock and loads up to 20 times the body weight.

There are many reasons why someone may experience articular knee cartilage damage. Regular wear and tear on the knee over time, involvement in high-stress activities, or accidents and injuries can all contribute to cartilage damage around the knee joint.

Osteoarthritis is a chronic degenerative disorder that ultimately leads to a gradual deterioration of knee joint cartilage. Osteoarthritis may also be the result of a prior injury to the knee joint such as a fracture, tendon damage, or ligament tears.

This may lead to joint instability, which can cause long-term damage to the articular cartilage. Arthritis can affect not only the cartilage but may also lead to damage of the bone beneath the cartilage, the synovial lining to the joint, ligaments, tendons, and muscles.

Adult stem cells are incredibly versatile in a medical sense. They have a potential to reliably differentiate into cartilage, bone, fat, or soft tissue. Because of this, the injection of progenitor cells, especially mesenchymal stem cells (special stem cells from adipose tissue or bone marrow), have been shown to be a better strategy to repair degenerative cartilage than implantation of differentiated cells such as articular cartilage.

In other words, when adult stem cells are injected into a knee with damaged cartilage, they can act to repair damaged tissue and build new cartilage.

Adult stem cells also display the ability to specifically address areas of inflammation and degeneration and to modify immune system activity, which can favorably influence the surrounding cartilage in areas of damage.

Encouragingly, results of pre-clinical and clinical trials have provided initial evidence of efficacy and safety in the therapeutic use of mesenchymal stem cell therapies for the treatment of knee cartilage damage and osteoarthritis. Cell-based therapy has become a key priority of tissue engineering research focused on functional replacement of cartilage and meniscus regeneration.

A year long animal study has provided research that demonstrates that stem cell treatments provide structural regeneration with mechanical properties comparable with the native cartilage.

The rest is here:
Stem Cell Therapy for Knees - thriveMD Denver & Vail, CO

Posted in Stem Cell Therapy | Comments Off

Stem cell therapy and autism | Raising Children Network

Posted: October 13, 2022 at 2:30 am

rn","memberOrganisations":[{"asset_name":"Parenting Research Centre","asset_redirect_url":"https://parentingrc.org.au","asset_metadata_page_content_svg_thumbnail^as_asset:asset_url":"https://raisingchildren.net.au/__data/assets/file/0017/23264/PRC_Stacked_MasterLogo_RGB.svg","asset_url":"https://parentingrc.org.au","asset_thumbnail_url":"https://raisingchildren.net.au/__data/assets/file/0017/23264/PRC_Stacked_MasterLogo_RGB.svg"},{"asset_name":"The Royal Children's Hospital Melbourne","asset_redirect_url":"https://www.rch.org.au","asset_metadata_page_content_svg_thumbnail^as_asset:asset_url":"https://raisingchildren.net.au/__data/assets/file/0016/23263/logo-chm.svg","asset_url":"https://www.rch.org.au","asset_thumbnail_url":"https://raisingchildren.net.au/__data/assets/file/0016/23263/logo-chm.svg"},{"asset_name":"Murdoch Children's Research Institute","asset_redirect_url":"https://www.mcri.edu.au/","asset_metadata_page_content_svg_thumbnail^as_asset:asset_url":"https://raisingchildren.net.au/__data/assets/file/0018/23265/logo-mcri.svg","asset_url":"https://www.mcri.edu.au/","asset_thumbnail_url":"https://raisingchildren.net.au/__data/assets/file/0018/23265/logo-mcri.svg"}]},"footerMenuBlocks":["a23224","a23232","a23240"]}; sq.ready( function() { return sq.siteTree }, function () { sq.globalFooter('global-footer', Object.assign({}, sq.state.site, {lineage: sq.state.page.lineage}, sq.state.footer, { siteTree: sq.siteTree, view: 'GlobalFooterInner' })); } ) })(sq);

Original post:
Stem cell therapy and autism | Raising Children Network

Posted in Stem Cell Therapy | Comments Off

Cellectis Presents Data on Two TALEN-based Gene Therapy Preclinical Programs for Patients with … – The Bakersfield Californian

Posted: October 13, 2022 at 2:30 am

NEW YORK, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Cellectis (the Company) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that the Company will present both an oral and poster at the European Society of Gene and Cell Therapys (ESGCT) 29th Congress, to be held in Edinburgh from October 11-14, 2022.

Arianna Moiani, Ph.D., Senior Scientist & Team Leader Innovation Gene Therapy, will give an oral presentation on encouraging pre-clinical data that leverages TALEN gene editing technology to develop a hematopoietic stem and progenitor cell (HSPCs)-based gene therapy to treat sickle cell disease.

Eduardo Seclen, Ph.D., Senior Scientist & Team Leader, Gene Editing, will present a poster illustrating a TALEN-based gene editing approach that reprograms HSPCs to secrete alpha-L-iduronidase (IDUA), a therapeutic enzyme missing in Mucopolysaccharidosis type I (MPS-I).

The pre-clinical data presented at ESGCT further demonstrate our ability to leverage TALEN gene editing technology to potentially address genetic diseases, namely, sickle cell disease and lysosomal storage diseases. By correcting a faulty mutation or inserting a corrected gene at the HSPC level, we aim to provide a lifelong supply of healthy cells in a single intervention, said Philippe Duchateau, Ph.D., Chief Scientific Officer at Cellectis. These new milestones bring us one step closer to our goal: providing a cure to patients that have failed to respond to standard therapy.

Presentation details

Pre-clinical data presentation on a non-viral DNA delivery associated with TALEN gene editing that leads to highly efficient correction of sickle cell mutation in long-term repopulating hematopoietic stem cells

Sickle cell disease stems from a single point mutation in the HBB gene which results in sickle hemoglobin.

Cellectis leveraged its TALEN technology to develop a gene editing process that leads to highly efficient HBB gene correction via homology directed repair, while mitigating potential risks associated to HBB gene knock-out.

Overall, these results show that non-viral DNA delivery associated with TALEN gene editing reduces the toxicity usually observed with viral DNA delivery and allows high levels of HBB gene correction in long-term repopulating hematopoietic stem cells.

The oral presentation titled Non-viral DNA delivery associated to TALEN gene editing leads to highly efficient correction of sickle cell mutation in long-term repopulating hematopoietic stem cells, will be made on Thursday, October 13th, 8:30AM-10:45AM BST by Arianna Moiani, Ph.D., Senior Scientist & Team Leader Innovation Gene Therapy. The presentation can be found on the Cellectis website on the day of the presentation.

Presentation details

Pre-clinical data presentation on TALEN-mediated engineering of HSPC that enables systemic delivery of IDUA

Mucopolysaccharidosis type I (MPS-I) is caused by deficiencies in the alpha-L-iduronidase (IDUA) gene and it is associated with severe morbidity representing a significant unmet medical need.

Cellectis established a TALEN-based ex vivo gene editing protocol to insert an IDUA-expression cassette into a specific locus of HSPC.

Editing rates in vivo were 6-9% sixteen weeks after injection, depending on the tissue analyzed (blood, spleen, bone marrow). Lastly, 8.3% of human cells were edited in the brain compartment.

Cellectis established a safe TALEN-based gene editing protocol procuring IDUA-edited HSPCs able to engraft, differentiate into multiple lineages and reach multiple tissues, including the brain.

The poster presentation titled TALEN-mediated engineering of HSPC enables systemic delivery of IDUA, will be made on Thursday, October 13th, 5:30PM - 7:15PM BST by Eduardo Seclen, Ph.D., Senior Scientist & Team Leader, Gene Editing, and can be found on Cellectis website.

About Cellectis

Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. Cellectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to make therapeutic gene editing in hemopoietic stem cells for various diseases. As a clinical-stage biopharmaceutical company with over 22 years of experience and expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to treat diseases with unmet medical needs. Cellectis headquarters are in Paris, France, with locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).

For more information, visit http://www.cellectis.com. Follow Cellectis on social media: @cellectis, LinkedIn and YouTube.

For further information, please contact:

Media contacts:

Pascalyne Wilson,Director,Communications,+33 (0)7 76 99 14 33, media@cellectis.com

Margaret Gandolfo, Senior Manager, Communications, +1 (646) 628 0300

Investor Relation contact:

Arthur Stril, Chief Business Officer, +1 (347) 809 5980, investors@cellectis.com

Ashley R. Robinson, LifeSci Advisors, +1 617430 7577

Forward-looking Statements

This press release contains forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as anticipate, believe, intend, expect, plan, scheduled, could, may and will, or the negative of these and similar expressions. These forward-looking statements, which are based on our managements current expectations and assumptions and on information currently available to management. Forward-looking statements include statements about the potential of our preclinical programs and product candidates. These forward-looking statements are made in light of information currently available to us and are subject to numerous risks and uncertainties, including with respect to the numerous risks associated with biopharmaceutical product candidate development. With respect to our cash runway, our operating plans, including product development plans, may change as a result of various factors, including factors currently unknown to us. Furthermore, many other important factors, including those described in our Annual Report on Form 20-F and the financial report (including the management report) for the year ended December 31, 2021 and subsequent filings Cellectis makes with the Securities Exchange Commission from time to time, as well as other known and unknown risks and uncertainties may adversely affect such forward-looking statements and cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

Attachment

See more here:
Cellectis Presents Data on Two TALEN-based Gene Therapy Preclinical Programs for Patients with ... - The Bakersfield Californian

Posted in Stem Cell Therapy | Comments Off

Global Nerve Repair and Regeneration Devices Market to Reach $12.9 Billion by 2027 – Yahoo Finance

Posted: October 13, 2022 at 2:30 am

ReportLinker

Abstract: Whats New for 2022?? Global competitiveness and key competitor percentage market shares. Market presence across multiple geographies - Strong/Active/Niche/Trivial.

New York, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Nerve Repair and Regeneration Devices Industry" - https://www.reportlinker.com/p05957490/?utm_source=GNW

Online interactive peer-to-peer collaborative bespoke updates

Access to our digital archives and MarketGlass Research Platform

Complimentary updates for one yearGlobal Nerve Repair and Regeneration Devices Market to Reach $12.9 Billion by 2027- In the changed post COVID-19 business landscape, the global market for Nerve Repair and Regeneration Devices estimated at US$6.6 Billion in the year 2020, is projected to reach a revised size of US$12.9 Billion by 2027, growing at aCAGR of 10% over the period 2020-2027. Neurostimulation & Neuromodulation Devices, one of the segments analyzed in the report, is projected to record 9.7% CAGR and reach US$10.9 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Biomaterials segment is readjusted to a revised 11.7% CAGR for the next 7-year period.- The U.S. Market is Estimated at $2 Billion, While China is Forecast to Grow at 13% CAGR- The Nerve Repair and Regeneration Devices market in the U.S. is estimated at US$2 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$2 Billion by the year 2027 trailing a CAGR of 13% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.7% and 8.8% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 9.2% CAGR.

Select Competitors (Total 61 Featured)Abbott Laboratories, Inc.AxoGen, Inc.Boston Scientific CorporationIntegra LifeSciences CorporationLivaNova, PLCMedtronic plcNeuroPace, Inc.Nevro Corporation.Orthomed S.A.S.Polyganics B.V.Stryker CorporationSynapse Biomedical Inc.Synovis Micro Companies Alliance, Inc.

Read the full report: https://www.reportlinker.com/p05957490/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY1. GLOBAL MARKET OVERVIEWImpact of Covid-19 and a Looming Global Recession2020 Marked as a Year of Disruption & TransformationWorld Economic Growth Projections (Real GDP, Annual % Change)for 2019 to 2022Global Nerve Repair & Regeneration Market Buckles under COVID-19 StrainCovid-19 Patients in Prone Position Suffering Nerve DamageBodes Well for Market GrowthNerve Repair and Regeneration Market Set for a Robust GrowthNeurostimulation & Neuromodulation Devices Hold Commanding Slotin Nerve Repair & Regeneration MarketBiomaterials to Exhibit Rapid GrowthNerve Repair and Regeneration Market by ApplicationUS and Europe Dominate the MarketAsia-Pacific and other Emerging Regions Display ImpressiveGrowth PotentialRecent Market Activity

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERSHigh Incidence of Neurological Disorders: A Key Market DriverAnnual Incidence of Adult-Onset Neurologic Disorders in the USEffects of COVID-19 on the Nervous System Sheds Focus onNeuromodulation ApplicationsIncreasing Cases of Peripheral Nerve Injuries Drive the NerveRepair and Regeneration MarketGrowing Number of Vehicular Accidents Drive the PeripheralNerve injuries Repair MarketRising Geriatric Population and Subsequent Growth in PrevalenceOf Neurological DisordersGlobal Population Statistics for the 65+ Age Group in Millionby Geographic Region for the Years 2019, 2025, 2035 and 2050Growing Incidence of Neurodegenerative Diseases Propels theMarket for Deep Brain Stimulation DevicesGlobal Alzheimers Prevalence by Age GroupDiagnosed Prevalence Cases of Parkinson?s Disease Across SelectCountriesGlobal DBS Market by Leading Player (2020E): Market ShareBreakdown of Revenues for Medtronic, Boston Scientific, andAbbottSelect Available Deep Brain Stimulation Devices Available inthe MarketIntensified Research Activity Across Various Neural DisciplinesInduces Additional OptimismStem Cell Therapy: A Promising Avenue for Nerve Repair andRegenerationIncreasing Cases of Epilepsy Drives the Demand for Vagus NerveStimulation DevicesEpilepsy Incidence by Type (2019): Percentage Share Breakdownfor Idiopathic and Symptomatic EpilepsySymptomatic Epilepsy Incidence by Type (2019): Percentage ShareBreakdown of Congenital, Degenerative, Infective, Neoplastic,Trauma, and Vascular EpilepsySpinal Cord Injuries Propel the Demand for Spinal CordStimulation DevicesRecent Developments in Spinal Cord Injury TreatmentBiomaterials (Nerve Conduits and Nerve Wraps) to Witness RapidGrowthNew Biomaterials Pave the Way for Innovative NeurodegenerationTherapiesRole of Nerve Conduits in the Treatment of Peripheral Nerve InjuryInnovative Nerve Conduits from StrykerTENS (Transcutaneous electrical nerve stimulation devices)Market Witnesses Rapid GrowthNon-Invasiveness of TMS (Transcranial Magnetic Stimulation)Propelling the adoption of TMS devicesNerve Grafts for Bridging Larger Nerve GapsRole of Nerve Grafting in Treatment of Peripheral Nerve InjuriesFDA-approved Nerve Tubes for Peripheral Nerve Repair

4. GLOBAL MARKET PERSPECTIVETable 1: World Recent Past, Current & Future Analysis for NerveRepair and Regeneration Devices by Geographic Region - USA,Canada, Japan, China, Europe, Asia-Pacific, Latin America,Middle East and Africa Markets - Independent Analysis of AnnualSales in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 2: World Historic Review for Nerve Repair andRegeneration Devices by Geographic Region - USA, Canada, Japan,China, Europe, Asia-Pacific, Latin America, Middle East andAfrica Markets - Independent Analysis of Annual Sales in US$Thousand for Years 2012 through 2019 and % CAGR

Table 3: World 15-Year Perspective for Nerve Repair andRegeneration Devices by Geographic Region - PercentageBreakdown of Value Sales for USA, Canada, Japan, China, Europe,Asia-Pacific, Latin America, Middle East and Africa Markets forYears 2012, 2021 & 2027

Table 4: World Recent Past, Current & Future Analysis forNeurostimulation & Neuromodulation Devices by Geographic Region -USA, Canada, Japan, China, Europe, Asia-Pacific, LatinAmerica, Middle East and Africa Markets - Independent Analysisof Annual Sales in US$ Thousand for Years 2020 through 2027and % CAGR

Table 5: World Historic Review for Neurostimulation &Neuromodulation Devices by Geographic Region - USA, Canada,Japan, China, Europe, Asia-Pacific, Latin America, Middle Eastand Africa Markets - Independent Analysis of Annual Sales inUS$ Thousand for Years 2012 through 2019 and % CAGR

Table 6: World 15-Year Perspective for Neurostimulation &Neuromodulation Devices by Geographic Region - PercentageBreakdown of Value Sales for USA, Canada, Japan, China, Europe,Asia-Pacific, Latin America, Middle East and Africa for Years2012, 2021 & 2027

Table 7: World Recent Past, Current & Future Analysis forBiomaterials by Geographic Region - USA, Canada, Japan, China,Europe, Asia-Pacific, Latin America, Middle East and AfricaMarkets - Independent Analysis of Annual Sales in US$ Thousandfor Years 2020 through 2027 and % CAGR

Table 8: World Historic Review for Biomaterials by GeographicRegion - USA, Canada, Japan, China, Europe, Asia-Pacific, LatinAmerica, Middle East and Africa Markets - Independent Analysisof Annual Sales in US$ Thousand for Years 2012 through 2019and % CAGR

Table 9: World 15-Year Perspective for Biomaterials byGeographic Region - Percentage Breakdown of Value Sales forUSA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,Middle East and Africa for Years 2012, 2021 & 2027

Table 10: World Recent Past, Current & Future Analysis forNeurostimulation & Neuromodulation Surgeries by GeographicRegion - USA, Canada, Japan, China, Europe, Asia-Pacific, LatinAmerica, Middle East and Africa Markets - Independent Analysisof Annual Sales in US$ Thousand for Years 2020 through 2027and % CAGR

Table 11: World Historic Review for Neurostimulation &Neuromodulation Surgeries by Geographic Region - USA, Canada,Japan, China, Europe, Asia-Pacific, Latin America, Middle Eastand Africa Markets - Independent Analysis of Annual Sales inUS$ Thousand for Years 2012 through 2019 and % CAGR

Table 12: World 15-Year Perspective for Neurostimulation &Neuromodulation Surgeries by Geographic Region - PercentageBreakdown of Value Sales for USA, Canada, Japan, China, Europe,Asia-Pacific, Latin America, Middle East and Africa for Years2012, 2021 & 2027

Table 13: World Recent Past, Current & Future Analysis forNeurorrhaphy by Geographic Region - USA, Canada, Japan, China,Europe, Asia-Pacific, Latin America, Middle East and AfricaMarkets - Independent Analysis of Annual Sales in US$ Thousandfor Years 2020 through 2027 and % CAGR

Table 14: World Historic Review for Neurorrhaphy by GeographicRegion - USA, Canada, Japan, China, Europe, Asia-Pacific, LatinAmerica, Middle East and Africa Markets - Independent Analysisof Annual Sales in US$ Thousand for Years 2012 through 2019and % CAGR

Table 15: World 15-Year Perspective for Neurorrhaphy byGeographic Region - Percentage Breakdown of Value Sales forUSA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,Middle East and Africa for Years 2012, 2021 & 2027

Table 16: World Recent Past, Current & Future Analysis forNerve Grafting by Geographic Region - USA, Canada, Japan,China, Europe, Asia-Pacific, Latin America, Middle East andAfrica Markets - Independent Analysis of Annual Sales in US$Thousand for Years 2020 through 2027 and % CAGR

Table 17: World Historic Review for Nerve Grafting byGeographic Region - USA, Canada, Japan, China, Europe,Asia-Pacific, Latin America, Middle East and Africa Markets -Independent Analysis of Annual Sales in US$ Thousand for Years2012 through 2019 and % CAGR

Table 18: World 15-Year Perspective for Nerve Grafting byGeographic Region - Percentage Breakdown of Value Sales forUSA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,Middle East and Africa for Years 2012, 2021 & 2027

Table 19: World Recent Past, Current & Future Analysis for StemCell Therapy by Geographic Region - USA, Canada, Japan, China,Europe, Asia-Pacific, Latin America, Middle East and AfricaMarkets - Independent Analysis of Annual Sales in US$ Thousandfor Years 2020 through 2027 and % CAGR

Table 20: World Historic Review for Stem Cell Therapy byGeographic Region - USA, Canada, Japan, China, Europe,Asia-Pacific, Latin America, Middle East and Africa Markets -Independent Analysis of Annual Sales in US$ Thousand for Years2012 through 2019 and % CAGR

Table 21: World 15-Year Perspective for Stem Cell Therapy byGeographic Region - Percentage Breakdown of Value Sales forUSA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,Middle East and Africa for Years 2012, 2021 & 2027

Table 22: World Recent Past, Current & Future Analysis forHospitals & Clinics by Geographic Region - USA, Canada, Japan,China, Europe, Asia-Pacific, Latin America, Middle East andAfrica Markets - Independent Analysis of Annual Sales in US$Thousand for Years 2020 through 2027 and % CAGR

Table 23: World Historic Review for Hospitals & Clinics byGeographic Region - USA, Canada, Japan, China, Europe,Asia-Pacific, Latin America, Middle East and Africa Markets -Independent Analysis of Annual Sales in US$ Thousand for Years2012 through 2019 and % CAGR

Table 24: World 15-Year Perspective for Hospitals & Clinics byGeographic Region - Percentage Breakdown of Value Sales forUSA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,Middle East and Africa for Years 2012, 2021 & 2027

Table 25: World Recent Past, Current & Future Analysis forAmbulatory Surgery Centers by Geographic Region - USA, Canada,Japan, China, Europe, Asia-Pacific, Latin America, Middle Eastand Africa Markets - Independent Analysis of Annual Sales inUS$ Thousand for Years 2020 through 2027 and % CAGR

Table 26: World Historic Review for Ambulatory Surgery Centersby Geographic Region - USA, Canada, Japan, China, Europe,Asia-Pacific, Latin America, Middle East and Africa Markets -Independent Analysis of Annual Sales in US$ Thousand for Years2012 through 2019 and % CAGR

Table 27: World 15-Year Perspective for Ambulatory SurgeryCenters by Geographic Region - Percentage Breakdown of ValueSales for USA, Canada, Japan, China, Europe, Asia-Pacific,Latin America, Middle East and Africa for Years 2012, 2021 &2027Impact of Covid-19 and a Looming Global Recession

III. MARKET ANALYSIS

UNITED STATESNerve Repair and Regeneration Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Statesfor 2022 (E)Table 28: USA Recent Past, Current & Future Analysis for NerveRepair and Regeneration Devices by Product - Neurostimulation &Neuromodulation Devices and Biomaterials - Independent Analysisof Annual Sales in US$ Thousand for the Years 2020 through 2027and % CAGR

Table 29: USA Historic Review for Nerve Repair and RegenerationDevices by Product - Neurostimulation & Neuromodulation Devicesand Biomaterials Markets - Independent Analysis of Annual Salesin US$ Thousand for Years 2012 through 2019 and % CAGR

Table 30: USA 15-Year Perspective for Nerve Repair andRegeneration Devices by Product - Percentage Breakdown of ValueSales for Neurostimulation & Neuromodulation Devices andBiomaterials for the Years 2012, 2021 & 2027

Table 31: USA Recent Past, Current & Future Analysis for NerveRepair and Regeneration Devices by Application -Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy,Nerve Grafting and Stem Cell Therapy - Independent Analysis ofAnnual Sales in US$ Thousand for the Years 2020 through 2027and % CAGR

Table 32: USA Historic Review for Nerve Repair and RegenerationDevices by Application - Neurostimulation & NeuromodulationSurgeries, Neurorrhaphy, Nerve Grafting and Stem Cell TherapyMarkets - Independent Analysis of Annual Sales in US$ Thousandfor Years 2012 through 2019 and % CAGR

Table 33: USA 15-Year Perspective for Nerve Repair andRegeneration Devices by Application - Percentage Breakdown ofValue Sales for Neurostimulation & Neuromodulation Surgeries,Neurorrhaphy, Nerve Grafting and Stem Cell Therapy for theYears 2012, 2021 & 2027

Table 34: USA Recent Past, Current & Future Analysis for NerveRepair and Regeneration Devices by End-Use - Hospitals &Clinics and Ambulatory Surgery Centers - Independent Analysisof Annual Sales in US$ Thousand for the Years 2020 through 2027and % CAGR

Table 35: USA Historic Review for Nerve Repair and RegenerationDevices by End-Use - Hospitals & Clinics and Ambulatory SurgeryCenters Markets - Independent Analysis of Annual Sales in US$Thousand for Years 2012 through 2019 and % CAGR

Table 36: USA 15-Year Perspective for Nerve Repair andRegeneration Devices by End-Use - Percentage Breakdown of ValueSales for Hospitals & Clinics and Ambulatory Surgery Centersfor the Years 2012, 2021 & 2027

CANADATable 37: Canada Recent Past, Current & Future Analysis forNerve Repair and Regeneration Devices by Product -Neurostimulation & Neuromodulation Devices and Biomaterials -Independent Analysis of Annual Sales in US$ Thousand for theYears 2020 through 2027 and % CAGR

Table 38: Canada Historic Review for Nerve Repair andRegeneration Devices by Product - Neurostimulation &Neuromodulation Devices and Biomaterials Markets - IndependentAnalysis of Annual Sales in US$ Thousand for Years 2012 through2019 and % CAGR

Table 39: Canada 15-Year Perspective for Nerve Repair andRegeneration Devices by Product - Percentage Breakdown of ValueSales for Neurostimulation & Neuromodulation Devices andBiomaterials for the Years 2012, 2021 & 2027

Table 40: Canada Recent Past, Current & Future Analysis forNerve Repair and Regeneration Devices by Application -Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy,Nerve Grafting and Stem Cell Therapy - Independent Analysis ofAnnual Sales in US$ Thousand for the Years 2020 through 2027and % CAGR

Table 41: Canada Historic Review for Nerve Repair andRegeneration Devices by Application - Neurostimulation &Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting andStem Cell Therapy Markets - Independent Analysis of AnnualSales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 42: Canada 15-Year Perspective for Nerve Repair andRegeneration Devices by Application - Percentage Breakdown ofValue Sales for Neurostimulation & Neuromodulation Surgeries,Neurorrhaphy, Nerve Grafting and Stem Cell Therapy for theYears 2012, 2021 & 2027

Table 43: Canada Recent Past, Current & Future Analysis forNerve Repair and Regeneration Devices by End-Use - Hospitals &Clinics and Ambulatory Surgery Centers - Independent Analysisof Annual Sales in US$ Thousand for the Years 2020 through 2027and % CAGR

Table 44: Canada Historic Review for Nerve Repair andRegeneration Devices by End-Use - Hospitals & Clinics andAmbulatory Surgery Centers Markets - Independent Analysis ofAnnual Sales in US$ Thousand for Years 2012 through 2019 and %CAGR

Table 45: Canada 15-Year Perspective for Nerve Repair andRegeneration Devices by End-Use - Percentage Breakdown of ValueSales for Hospitals & Clinics and Ambulatory Surgery Centersfor the Years 2012, 2021 & 2027

JAPANNerve Repair and Regeneration Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E)Table 46: Japan Recent Past, Current & Future Analysis forNerve Repair and Regeneration Devices by Product -Neurostimulation & Neuromodulation Devices and Biomaterials -Independent Analysis of Annual Sales in US$ Thousand for theYears 2020 through 2027 and % CAGR

Table 47: Japan Historic Review for Nerve Repair andRegeneration Devices by Product - Neurostimulation &Neuromodulation Devices and Biomaterials Markets - IndependentAnalysis of Annual Sales in US$ Thousand for Years 2012 through2019 and % CAGR

Table 48: Japan 15-Year Perspective for Nerve Repair andRegeneration Devices by Product - Percentage Breakdown of ValueSales for Neurostimulation & Neuromodulation Devices andBiomaterials for the Years 2012, 2021 & 2027

Table 49: Japan Recent Past, Current & Future Analysis forNerve Repair and Regeneration Devices by Application -Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy,Nerve Grafting and Stem Cell Therapy - Independent Analysis ofAnnual Sales in US$ Thousand for the Years 2020 through 2027and % CAGR

Table 50: Japan Historic Review for Nerve Repair andRegeneration Devices by Application - Neurostimulation &Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting andStem Cell Therapy Markets - Independent Analysis of AnnualSales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 51: Japan 15-Year Perspective for Nerve Repair andRegeneration Devices by Application - Percentage Breakdown ofValue Sales for Neurostimulation & Neuromodulation Surgeries,Neurorrhaphy, Nerve Grafting and Stem Cell Therapy for theYears 2012, 2021 & 2027

Table 52: Japan Recent Past, Current & Future Analysis forNerve Repair and Regeneration Devices by End-Use - Hospitals &Clinics and Ambulatory Surgery Centers - Independent Analysisof Annual Sales in US$ Thousand for the Years 2020 through 2027and % CAGR

Table 53: Japan Historic Review for Nerve Repair andRegeneration Devices by End-Use - Hospitals & Clinics andAmbulatory Surgery Centers Markets - Independent Analysis ofAnnual Sales in US$ Thousand for Years 2012 through 2019 and %CAGR

Table 54: Japan 15-Year Perspective for Nerve Repair andRegeneration Devices by End-Use - Percentage Breakdown of ValueSales for Hospitals & Clinics and Ambulatory Surgery Centersfor the Years 2012, 2021 & 2027

CHINANerve Repair and Regeneration Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E)Table 55: China Recent Past, Current & Future Analysis forNerve Repair and Regeneration Devices by Product -Neurostimulation & Neuromodulation Devices and Biomaterials -Independent Analysis of Annual Sales in US$ Thousand for theYears 2020 through 2027 and % CAGR

Table 56: China Historic Review for Nerve Repair andRegeneration Devices by Product - Neurostimulation &Neuromodulation Devices and Biomaterials Markets - IndependentAnalysis of Annual Sales in US$ Thousand for Years 2012 through2019 and % CAGR

Table 57: China 15-Year Perspective for Nerve Repair andRegeneration Devices by Product - Percentage Breakdown of ValueSales for Neurostimulation & Neuromodulation Devices andBiomaterials for the Years 2012, 2021 & 2027

Table 58: China Recent Past, Current & Future Analysis forNerve Repair and Regeneration Devices by Application -Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy,Nerve Grafting and Stem Cell Therapy - Independent Analysis ofAnnual Sales in US$ Thousand for the Years 2020 through 2027and % CAGR

Table 59: China Historic Review for Nerve Repair andRegeneration Devices by Application - Neurostimulation &Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting andStem Cell Therapy Markets - Independent Analysis of AnnualSales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 60: China 15-Year Perspective for Nerve Repair andRegeneration Devices by Application - Percentage Breakdown ofValue Sales for Neurostimulation & Neuromodulation Surgeries,Neurorrhaphy, Nerve Grafting and Stem Cell Therapy for theYears 2012, 2021 & 2027

Table 61: China Recent Past, Current & Future Analysis forNerve Repair and Regeneration Devices by End-Use - Hospitals &Clinics and Ambulatory Surgery Centers - Independent Analysisof Annual Sales in US$ Thousand for the Years 2020 through 2027and % CAGR

Table 62: China Historic Review for Nerve Repair andRegeneration Devices by End-Use - Hospitals & Clinics andAmbulatory Surgery Centers Markets - Independent Analysis ofAnnual Sales in US$ Thousand for Years 2012 through 2019 and %CAGR

Table 63: China 15-Year Perspective for Nerve Repair andRegeneration Devices by End-Use - Percentage Breakdown of ValueSales for Hospitals & Clinics and Ambulatory Surgery Centersfor the Years 2012, 2021 & 2027

EUROPENerve Repair and Regeneration Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E)Table 64: Europe Recent Past, Current & Future Analysis forNerve Repair and Regeneration Devices by Geographic Region -France, Germany, Italy, UK, Spain, Russia and Rest of EuropeMarkets - Independent Analysis of Annual Sales in US$ Thousandfor Years 2020 through 2027 and % CAGR

Table 65: Europe Historic Review for Nerve Repair andRegeneration Devices by Geographic Region - France, Germany,Italy, UK, Spain, Russia and Rest of Europe Markets -Independent Analysis of Annual Sales in US$ Thousand for Years2012 through 2019 and % CAGR

Table 66: Europe 15-Year Perspective for Nerve Repair andRegeneration Devices by Geographic Region - PercentageBreakdown of Value Sales for France, Germany, Italy, UK, Spain,Russia and Rest of Europe Markets for Years 2012, 2021 & 2027

Table 67: Europe Recent Past, Current & Future Analysis forNerve Repair and Regeneration Devices by Product -Neurostimulation & Neuromodulation Devices and Biomaterials -Independent Analysis of Annual Sales in US$ Thousand for theYears 2020 through 2027 and % CAGR

Table 68: Europe Historic Review for Nerve Repair andRegeneration Devices by Product - Neurostimulation &Neuromodulation Devices and Biomaterials Markets - IndependentAnalysis of Annual Sales in US$ Thousand for Years 2012 through2019 and % CAGR

Table 69: Europe 15-Year Perspective for Nerve Repair andRegeneration Devices by Product - Percentage Breakdown of ValueSales for Neurostimulation & Neuromodulation Devices andBiomaterials for the Years 2012, 2021 & 2027

Table 70: Europe Recent Past, Current & Future Analysis forNerve Repair and Regeneration Devices by Application -Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy,Nerve Grafting and Stem Cell Therapy - Independent Analysis ofAnnual Sales in US$ Thousand for the Years 2020 through 2027and % CAGR

Table 71: Europe Historic Review for Nerve Repair andRegeneration Devices by Application - Neurostimulation &Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting andStem Cell Therapy Markets - Independent Analysis of AnnualSales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 72: Europe 15-Year Perspective for Nerve Repair andRegeneration Devices by Application - Percentage Breakdown ofValue Sales for Neurostimulation & Neuromodulation Surgeries,Neurorrhaphy, Nerve Grafting and Stem Cell Therapy for theYears 2012, 2021 & 2027

Table 73: Europe Recent Past, Current & Future Analysis forNerve Repair and Regeneration Devices by End-Use - Hospitals &Clinics and Ambulatory Surgery Centers - Independent Analysisof Annual Sales in US$ Thousand for the Years 2020 through 2027and % CAGR

Table 74: Europe Historic Review for Nerve Repair andRegeneration Devices by End-Use - Hospitals & Clinics andAmbulatory Surgery Centers Markets - Independent Analysis ofAnnual Sales in US$ Thousand for Years 2012 through 2019 and %CAGR

Table 75: Europe 15-Year Perspective for Nerve Repair andRegeneration Devices by End-Use - Percentage Breakdown of ValueSales for Hospitals & Clinics and Ambulatory Surgery Centersfor the Years 2012, 2021 & 2027

FRANCENerve Repair and Regeneration Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E)Table 76: France Recent Past, Current & Future Analysis forNerve Repair and Regeneration Devices by Product -Neurostimulation & Neuromodulation Devices and Biomaterials -Independent Analysis of Annual Sales in US$ Thousand for theYears 2020 through 2027 and % CAGR

Table 77: France Historic Review for Nerve Repair andRegeneration Devices by Product - Neurostimulation &Neuromodulation Devices and Biomaterials Markets - IndependentAnalysis of Annual Sales in US$ Thousand for Years 2012 through2019 and % CAGR

Table 78: France 15-Year Perspective for Nerve Repair andRegeneration Devices by Product - Percentage Breakdown of ValueSales for Neurostimulation & Neuromodulation Devices andBiomaterials for the Years 2012, 2021 & 2027

Table 79: France Recent Past, Current & Future Analysis forNerve Repair and Regeneration Devices by Application -Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy,Nerve Grafting and Stem Cell Therapy - Independent Analysis ofAnnual Sales in US$ Thousand for the Years 2020 through 2027and % CAGR

Table 80: France Historic Review for Nerve Repair andRegeneration Devices by Application - Neurostimulation &Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting andStem Cell Therapy Markets - Independent Analysis of AnnualSales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 81: France 15-Year Perspective for Nerve Repair andRegeneration Devices by Application - Percentage Breakdown ofValue Sales for Neurostimulation & Neuromodulation Surgeries,Neurorrhaphy, Nerve Grafting and Stem Cell Therapy for theYears 2012, 2021 & 2027

Table 82: France Recent Past, Current & Future Analysis forNerve Repair and Regeneration Devices by End-Use - Hospitals &Clinics and Ambulatory Surgery Centers - Independent Analysisof Annual Sales in US$ Thousand for the Years 2020 through 2027and % CAGR

Table 83: France Historic Review for Nerve Repair andRegeneration Devices by End-Use - Hospitals & Clinics andAmbulatory Surgery Centers Markets - Independent Analysis ofAnnual Sales in US$ Thousand for Years 2012 through 2019 and %CAGR

Table 84: France 15-Year Perspective for Nerve Repair andRegeneration Devices by End-Use - Percentage Breakdown of ValueSales for Hospitals & Clinics and Ambulatory Surgery Centersfor the Years 2012, 2021 & 2027

GERMANYNerve Repair and Regeneration Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022:(E)Table 85: Germany Recent Past, Current & Future Analysis forNerve Repair and Regeneration Devices by Product -Neurostimulation & Neuromodulation Devices and Biomaterials -Independent Analysis of Annual Sales in US$ Thousand for theYears 2020 through 2027 and % CAGR

Table 86: Germany Historic Review for Nerve Repair andRegeneration Devices by Product - Neurostimulation &Neuromodulation Devices and Biomaterials Markets - IndependentAnalysis of Annual Sales in US$ Thousand for Years 2012 through2019 and % CAGR

Table 87: Germany 15-Year Perspective for Nerve Repair andRegeneration Devices by Product - Percentage Breakdown of ValueSales for Neurostimulation & Neuromodulation Devices andBiomaterials for the Years 2012, 2021 & 2027

See more here:
Global Nerve Repair and Regeneration Devices Market to Reach $12.9 Billion by 2027 - Yahoo Finance

Posted in Stem Cell Therapy | Comments Off

2023 to be highly lucrative for drug developers across therapeutic areas: Report – BSI bureau

Posted: October 13, 2022 at 2:30 am

Citeline shares insights on a longer-term outlook at some key late-stage drugs projected to hit the market in 2023

Citeline(formerly Informa Pharma Intelligence) has recently published the Key Potential Drug Launches in 2023 report sharing insights on a longer-term outlook of some key late-stage drugs projected to hit the market in 2023.

Chronic Heart Failure (CHF) remains a key area of attention for drug makers. In this scenario, Furoscix is a reformulation of the diuretic furosemide which has been developed for the treatment of decompensated heart failure and designed to be self-administered in the outpatient setting through a subcutaneous infusion via a wearable, on-body drug delivery system. Currently, the Prescription Drug User Fee Act (PDUFA) date for Furoscix is set at October 8 2022 following a resubmission of an NDA in April 2022 which included data from the Phase III FREEDOM HF trial, where the overall and heart failure-related costs of treating congestion in patients with CHF were investigated.

Simultaneously, Omecamtiv Mecarbil is another soon-to-be-launched drug, which will provide additional means of improving outcomes on top of the standard of care for those patients with more advanced stages of CHF.

In the Oncology space, for Bone Marrow Transplant and Stem Cell Transplant, Gamida Cells omidubicel is a nicotinamide (NAM)-enabled stem cell therapy being studied for use in allogeneic hematopoietic (bone marrow) stem cell transplants for patients with hematologic malignancies like acute lymphocytic leukemia.

In June 2022, Gamida Cell completed its submission to the FDA for omidubicels biologics license application, with a final decision expected in June 2023 if there are no delays.

Breyanzi has demonstrated encouraging results in the Phase I/II TRANSCEND-CLL-004 trial, reporting higher observed overall response rates compared to other investigational CD 19-directed CAR-T therapies, such as Kymriah. Breyanzi looks set to emerge as a revolutionary option for this last-line treatment setting, pending its supplemental approval in 2023.

For Haematology, Vertex had announced that global regulatory filings for exa-cel (CTX001) in transfusion-dependent beta-thalassemia (TDT) and sickle cell disease are expected by the end of 2022 which if successful, could in 2023 make it the first CRISPR/Cas 9 based product ever approved, an important boost for the gene editing technology.

Go here to read the rest:
2023 to be highly lucrative for drug developers across therapeutic areas: Report - BSI bureau

Posted in Stem Cell Therapy | Comments Off

Monthly Archives: October 2022

Husband and Wife Team Bring Regenerative Medicine Clinic to Jackson – Franchising.com

Hundreds run for regenerative medicine research at the 2022 TCS London Marathon – British Heart Foundation

Frequency Therapeutics Completes Enrollment of Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss – Yahoo Finance

3D Bioprinting Market Size to Touch Valuation of $1.5 Billion by 2028 | Inkjet Technology Generates More than 38% Revenue of Bioprinting Market -…

SANUWAVE’s Energy First Technology to be Featured in 3 Clinical Posters at Upcoming 2022 Fall Symposium on Advanced Wound Care (SAWC) -…

Stem Cell Therapy for Knees – thriveMD Denver & Vail, CO

Stem cell therapy and autism | Raising Children Network

Cellectis Presents Data on Two TALEN-based Gene Therapy Preclinical Programs for Patients with … – The Bakersfield Californian

Global Nerve Repair and Regeneration Devices Market to Reach $12.9 Billion by 2027 – Yahoo Finance

2023 to be highly lucrative for drug developers across therapeutic areas: Report – BSI bureau

Categories

Archives

Recommended Sites

Contact Us

Recent Posts